ClinicalTrials.gg
CompletedNCT01744808Updated Apr 13, 2026

A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020

A Phase 1 interventional study of EB-1020 IR and EB-1020 SR1 in Normal, Healthy Volunteers, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To investigate whether there is a food-effect with oral administration with EB-1020 as well as to obtain information on the safety, and tolerability of EB-1020 in a range of doses.

Read the detailed description
  • To investigate the safety and tolerance of single doses of EB-1020 immediate release (IR) versus three sustained release (SR) formulations.
  • To investigate the safety and tolerance of a single oral dose of a SR formulation of EB-1020 in the fed and fasted state.
  • To investigate the safety, tolerance, and cognitive effects of multiple oral rising doses of a SR formulation of EB-1020.

Secondary Objectives

  • To characterize the single dose and steady state pharmacokinetic profiles of EB-1020 SR formulations.
  • To investigate the effect of food on the pharmacokinetic profile of EB-1020 SR following single oral doses.
02

Conditions studied

  • Normal, Healthy Volunteers

Keywords

  • Healthy
  • Normal
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-45 years inclusive
  2. Body weight with the normal range for height ( [BMI] between 19-30 kg/m2 inclusive)
  3. If female, be of non-child bearing potential (surgically sterile, for 12 months or receiving a stable dose of implanted or injectable for at least 3 months with last dose of injectable contraceptive within 2 months). Non-surgical menopause history must be confirmed by follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels as defined by established lab ranges.
  4. Be in general good health without medical history
  5. Have clinical laboratory test results that are within the laboratory reference range; or if out of range are not clinically relevant and are acceptable to the Investigator and Sponsor medical representative
  6. Negative (HIV), and Hepatitis Screening test
  7. Able and willing to give written

Exclusion criteria

Exclusion Criteria:

  1. Receipt of any agent or drug within 3 months of entry into the study
  2. Use of prescription drugs within 4 weeks prior to first dosing. Subjects who have used over the counter medication excluding paracetamol, topical over the counter medications and routine vitamins but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 7 days of first dosing, unless agreed as non- by the Principal Investigator and Sponsor
  3. A history of, or current evidence for, suicidal ideation, based upon clinical interview and a psychiatric questionnaire
  4. A history of known or suspected seizures, spasms, infantile spasms, febrile convulsions, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits)
  5. A history of sleep problems in the last 3 months
  6. A history of relevant atopy or drug
  7. A history (within the last 5 years) or evidence of alcohol or drug abuse. Subject who consume more than 14 units (female) or 21 (male) units of alcohol a week (unit = 1 glass (125 mL) of wine = 1 measure of spirits = ½ pint of beer) will also be ineligible
  8. A positive urine test for drugs of abuse or alcohol at Screening or on the day of admittance to the Study Unit
  9. A history of smoking in the last 3 months
  10. Have a significant infection (such as influenza) or known inflammatory process on screening or admission
  11. Have acute gastrointestinal symptoms at the time of screening or admission (e.g. nausea, vomiting, diarrhea, heartburn )
  12. Have previously received EB-1020
  13. Be vegetarians, vegans or have medical dietary restrictions
  14. Any major surgical procedure within one month of entry into the study
  15. Have difficulties communicating reliably with the Investigator or appear unlikely to co-operate with the requirements of the study in the investigator's judgment.
  16. Any other condition which in the view of the Investigator is likely to interfere with study or put the subject at risk.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Active comparator
    EB-1020 SR1

    Sustained release formulation

    Drug: EB-1020 SR1

  • Active comparator
    EB-1020 SR2

    Sustained Release Formulation

    Drug: EB-1020 SR2

  • Active comparator
    EB-1020 SR3

    Sustained Release Formulation

    Drug: EB-1020 SR3

  • Active comparator
    EB-1020 IR

    Immediate Release Formulation

    Drug: EB-1020 IR

  • Placebo comparator
    Placebo

    Placebo Formulation

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Pharmacokinetic parameters

    Time frame: up to 6 months

  2. Tmax

    Pharmacokinetic parameter

    Time frame: up to 6 months

  3. AUC

    Pharmacokinetic parameter

    Time frame: up to 6 months

Secondary outcomes

  1. Effect of food on Cmax

    Time frame: up to 6 months

07

Study locations

1 site
  • Nucleus Network Ltd.
    Melbourne, Victoria 3004, Australia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2013 to primary completion in Feb 2014, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2012
First posted
Dec 7, 2012
StartActual
Feb 1, 2013
Primary completionActual
Feb 1, 2014
CompletionActual
Feb 1, 2014
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01744808
Responsible party
Sponsor
First posted
Dec 7, 2012
Start date
Feb 1, 2013
Primary completion
Feb 1, 2014
Completion
Feb 1, 2014
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Centanafadine

Start the discussion